Consensus Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
129.78 ^USD	+1.57%		+1.29%	-8.50%

09/03	Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08:40 AM
04/03	Neurocrine Biosciences, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 11:50 AM

Evolution of the Average Target: Neurocrine Biosciences, Inc.

Evolution of the Target Price: Neurocrine Biosciences, Inc.

Changes in Analyst Recommendations: Neurocrine Biosciences, Inc.

736811fb.hz_DduoorQXd0F7QxbjWYBKXOFHPtkYAUkCVgnL2QCQ.8VOGD65bz3y_6QaDps6CNnzuTyKQ5wplJg3g1QKRJl7idqUev236U5GYGw~d4051470194da2eda394325781179ec4

Analysts' recommendations: Neurocrine Biosciences, Inc.

13/02	UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating	MT
12/02	Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says	MT
12/02	Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating	MT
12/02	RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating	MT
12/02	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $175, Keeps Equalweight Rating	MT
23/01	UBS Adjusts Price Target on Neurocrine Biosciences to $178 From $188, Maintains Buy Rating	MT
08/01	Morgan Stanley Downgrades Neurocrine Biosciences to Equalweight From Overweight, Adjusts Price Target to $175 From $173	MT
08/12	RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating	MT
01/12	Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating	MT
11/11	Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $178, Keeps Overweight Rating	MT
11/11	Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study	MT
11/11	Neurocrine Biosciences, Inc. Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder	CI
29/25/29	Wedbush Raises Price Target on Neurocrine Biosciences to $149 From $143, Keeps Outperform Rating	MT
29/25/29	Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating	MT
29/25/29	RBC Raises Price Target on Neurocrine Biosciences to $160 From $156, Keeps Outperform Rating	MT
29/25/29	Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating	MT
20/25/20	RBC Raises Price Target on Neurocrine Biosciences to $168 From $163, Keeps Overweight Rating	MT
17/25/17	Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGreZZA® (valbenazine) Capsules	CI
14/25/14	Wedbush Lifts Price Target on Neurocrine Biosciences to $143 From $141, Keeps Outperform Rating	MT
09/25/09	UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating	MT
08/25/08	RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating	MT
05/25/05	RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating	MT
31/25/31	RBC Trims Price Target on Neurocrine Biosciences to $144 From $146, Keeps Outperform Rating	MT
31/25/31	Morgan Stanley Raises Price Target on Neurocrine Biosciences to $158 From $150, Keeps Overweight Rating	MT
31/25/31	Biopharma firm Neurocrine Q2 adjusted EPS beats estimates	RE

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NEUROCRINE BIOSCIENCES, INC.					+37.19%
	ELI LILLY AND COMPANY					+23.54%
	JOHNSON & JOHNSON					-1.34%
	ABBVIE INC.					+13.28%
	ROCHE HOLDING AG					+13.34%
	ASTRAZENECA PLC					+15.73%
	NOVARTIS AG					-1.61%
	MERCK & CO., INC.					+10.52%
	AMGEN INC.					-4.42%
	GILEAD SCIENCES, INC.					+8.58%
	Average					+11.48%
	Weighted average by Cap.					+10.98%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

129.78USD

Average target price

178.04USD

Spread / Average Target

+37.19%

High Price Target

217.15USD

Spread / Highest target

+67.32%

Low Price Target

140.00USD

Spread / Lowest Target

+7.87%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Wedbush
RBC Capital Markets
Morgan Stanley
Deutsche Bank Securities
Truist Securities
BofA Securities
Needham & Co.
Oppenheimer
Wells Fargo Securities
JPMorgan Chase
Citigroup
Mizuho Securities
Goldman Sachs
Barclays
Stifel Nicolaus
Piper Sandler
Raymond James
Jefferies & Co.
HC Wainwright
Canaccord Genuity
BMO Capital
Baird
Guggenheim
Evercore ISI
SVB Securities LLC
Royal Bank of Canada
Cantor Fitzgerald
J.P. Morgan Chase
SVB Leerink
Credit Suisse